0001214659-17-003555.txt : 20170522
0001214659-17-003555.hdr.sgml : 20170522
20170522204512
ACCESSION NUMBER: 0001214659-17-003555
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170520
FILED AS OF DATE: 20170522
DATE AS OF CHANGE: 20170522
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Anthera Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001316175
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 201852016
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
BUSINESS PHONE: (510) 856-5600
MAIL ADDRESS:
STREET 1: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dickinson Klara
CENTRAL INDEX KEY: 0001339895
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34637
FILM NUMBER: 17862491
MAIL ADDRESS:
STREET 1: 5000 SHORELINE COURT, SUITE 101
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
marketforms-38869.xml
PRIMARY DOCUMENT
X0306
4
2017-05-20
0001316175
Anthera Pharmaceuticals Inc
ANTH
0001339895
Dickinson Klara
25801 INDUSTRIAL BLVD., SUITE B
HAYWARD
CA
94545
false
true
false
false
Chief Regulatory Officer
Stock option (right to buy)
1.63
2017-05-20
4
A
false
43750
0
A
2027-05-20
Common Stock
43750
43750
D
This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027.
/s/ Klara Dickinson
2017-05-22